Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pileri

Showing results (931-940 of 992) with videos related to

Pageof 100
Sort By:
Blood|January 27, 2011
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformationDavide Rossi, Valeria Spina, Clara Deambrogi, et al.
The Lancet. Oncology|March 18, 2008
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)Pier Luigi Zinzani, Monica Tani, Alessandro Pulsoni, et al.
The Lancet. Haematology|February 28, 2020
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell ProjectChristopher P Fox, Monica Civallero, Young-Hyeh Ko, et al.
The Lancet. Oncology|July 3, 2017
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 studyAnnalisa Chiappella, Maurizio Martelli, Emanuele Angelucci, et al.
Blood|May 14, 2011
Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma projectJan Delabie, Harald Holte, Julie M Vose, et al.
Blood|December 19, 2013
A targeted mutational landscape of angioimmunoblastic T-cell lymphomaOreofe Odejide, Oliver Weigert, Andrew A Lane, et al.
Blood|February 2, 2008
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantageMarco Ladetto, Federica De Marco, Fabio Benedetti, et al.
Blood|August 15, 2002
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)Marco Ladetto, Paolo Corradini, Sonia Vallet, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2017
Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomasFrancesco Abate, Ana C da Silva-Almeida, Sakellarios Zairis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2013
Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy studyPier Paolo Piccaluga, Fabio Fuligni, Antonio De Leo, et al.
Pageof 100

Showing results (931-940 of 992) with videos related to

Sort By:
Pageof 100
Blood|January 27, 2011
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformationDavide Rossi, Valeria Spina, Clara Deambrogi, et al.
The Lancet. Oncology|March 18, 2008
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)Pier Luigi Zinzani, Monica Tani, Alessandro Pulsoni, et al.
The Lancet. Haematology|February 28, 2020
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell ProjectChristopher P Fox, Monica Civallero, Young-Hyeh Ko, et al.
The Lancet. Oncology|July 3, 2017
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 studyAnnalisa Chiappella, Maurizio Martelli, Emanuele Angelucci, et al.
Blood|May 14, 2011
Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma projectJan Delabie, Harald Holte, Julie M Vose, et al.
Blood|December 19, 2013
A targeted mutational landscape of angioimmunoblastic T-cell lymphomaOreofe Odejide, Oliver Weigert, Andrew A Lane, et al.
Blood|February 2, 2008
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantageMarco Ladetto, Federica De Marco, Fabio Benedetti, et al.
Blood|August 15, 2002
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)Marco Ladetto, Paolo Corradini, Sonia Vallet, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2017
Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomasFrancesco Abate, Ana C da Silva-Almeida, Sakellarios Zairis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2013
Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy studyPier Paolo Piccaluga, Fabio Fuligni, Antonio De Leo, et al.
Pageof 100